• Return to Headlines

Becton Dickinson: The Winning Streak Continues (BDX)

By James Quinn

Becton Dickinson (NYSE:BDX) traded today at a new 52-week high of $197.99. This new high was reached on below average trading volume as 108,000 shares traded hands, while the average 30-day volume is approximately 885,000 shares.

There is potential upside of 1.9% for shares of Becton Dickinson based on a current price of $197.50 and an average consensus analyst price target of $201.31. The stock should find initial support at its 50-day moving average (MA) of $153.96 and further support at its 200-day MA of $147.03.

Over the past year, Becton Dickinson has traded in a range of $161.29 to $197.99 and is now at $197.50, 22% above that low. Over the last five market days, the 200-day moving average (MA) has gone up 0.2% while the 50-day MA has advanced 0.8%.

Becton, Dickinson and Company is a global medical technology company engaged principally in the development, manufacture, and sale of medical devices, instrument systems, and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public.

SmarTrend recommended that subscribers consider buying shares of Becton Dickinson on January 10th, 2017 as our proprietary SmarTrend analytics indicated a new Uptrend was in progress when shares hit $170.63. Since that recommendation, shares of Becton Dickinson have risen 15.9%. We continue to monitor BDX for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.

Keywords: 52 week high/lows becton dickinson

Ticker(s): BDX